SG11202104084WA - Methods for allogeneic hematopoietic stem cell transplantation - Google Patents
Methods for allogeneic hematopoietic stem cell transplantationInfo
- Publication number
- SG11202104084WA SG11202104084WA SG11202104084WA SG11202104084WA SG11202104084WA SG 11202104084W A SG11202104084W A SG 11202104084WA SG 11202104084W A SG11202104084W A SG 11202104084WA SG 11202104084W A SG11202104084W A SG 11202104084WA SG 11202104084W A SG11202104084W A SG 11202104084WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- stem cell
- hematopoietic stem
- cell transplantation
- allogeneic hematopoietic
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752828P | 2018-10-30 | 2018-10-30 | |
US201862773873P | 2018-11-30 | 2018-11-30 | |
US201962882362P | 2019-08-02 | 2019-08-02 | |
PCT/US2019/058973 WO2020092655A1 (en) | 2018-10-30 | 2019-10-30 | Methods for allogeneic hematopoietic stem cell transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104084WA true SG11202104084WA (en) | 2021-05-28 |
Family
ID=70462151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104084WA SG11202104084WA (en) | 2018-10-30 | 2019-10-30 | Methods for allogeneic hematopoietic stem cell transplantation |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210379195A1 (en) |
EP (1) | EP3877415A4 (en) |
JP (1) | JP2022512781A (en) |
KR (1) | KR20210086683A (en) |
CN (1) | CN113301923A (en) |
AU (1) | AU2019374055A1 (en) |
BR (1) | BR112021008437A2 (en) |
CA (1) | CA3117366A1 (en) |
IL (1) | IL282637A (en) |
MX (1) | MX2021004579A (en) |
SG (1) | SG11202104084WA (en) |
WO (1) | WO2020092655A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
JP2022530438A (en) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | Anti-CD117 antibody drug conjugate and its use |
WO2020219778A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
JP2022530442A (en) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | Anthracycline antibody drug conjugate and its use |
WO2023091954A2 (en) | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy |
AU2022421979A1 (en) * | 2021-12-22 | 2024-08-01 | The Jackson Laboratory | Humanized mouse models |
CA3240875A1 (en) * | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
WO2023164744A1 (en) * | 2022-03-01 | 2023-09-07 | CSL Innovation Pty Ltd | Methods of bone marrow conditioning |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2738115T3 (en) * | 2010-08-18 | 2020-01-20 | Theresa Deisher | Dexamethasone for use in the treatment of osteoarthritis, liver failure, type-2 diabetes mellitus, stroke and Parkinson's disease, in combination with a stem cell treatment |
BR112017021536A2 (en) * | 2015-04-06 | 2018-07-03 | Harvard College | compositions and methods for nonmyeloablative conditioning |
BR112018076263A2 (en) * | 2016-06-17 | 2019-03-26 | Magenta Therapeutics, Inc. | compositions and methods for cell depletion |
MX2018015684A (en) * | 2016-06-17 | 2019-08-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells. |
-
2019
- 2019-10-30 MX MX2021004579A patent/MX2021004579A/en unknown
- 2019-10-30 AU AU2019374055A patent/AU2019374055A1/en active Pending
- 2019-10-30 CN CN201980085584.8A patent/CN113301923A/en active Pending
- 2019-10-30 SG SG11202104084WA patent/SG11202104084WA/en unknown
- 2019-10-30 JP JP2021521816A patent/JP2022512781A/en active Pending
- 2019-10-30 KR KR1020217016249A patent/KR20210086683A/en unknown
- 2019-10-30 EP EP19877673.4A patent/EP3877415A4/en active Pending
- 2019-10-30 CA CA3117366A patent/CA3117366A1/en active Pending
- 2019-10-30 WO PCT/US2019/058973 patent/WO2020092655A1/en unknown
- 2019-10-30 BR BR112021008437-1A patent/BR112021008437A2/en unknown
-
2021
- 2021-04-26 IL IL282637A patent/IL282637A/en unknown
- 2021-04-29 US US17/244,864 patent/US20210379195A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3117366A1 (en) | 2020-05-07 |
BR112021008437A2 (en) | 2021-09-28 |
AU2019374055A1 (en) | 2021-06-17 |
US20210379195A1 (en) | 2021-12-09 |
EP3877415A4 (en) | 2022-11-30 |
CN113301923A (en) | 2021-08-24 |
KR20210086683A (en) | 2021-07-08 |
JP2022512781A (en) | 2022-02-07 |
EP3877415A1 (en) | 2021-09-15 |
IL282637A (en) | 2021-06-30 |
WO2020092655A1 (en) | 2020-05-07 |
MX2021004579A (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282637A (en) | Methods for allogeneic hematopoietic stem cell transplantation | |
IL269203A (en) | Compositions and methods for selective elimination and replacement of hematopoietic stem cells | |
EP3384007A4 (en) | Improved methods for reprograming non-pluripotent cells into pluripotent stem cells | |
EP3749334A4 (en) | Methods for allogenic hematopoietic stem cell transplantation | |
SG11201706886PA (en) | Cell culture method for mesenchymal stem cells | |
HK1258528A1 (en) | Methods and compositions for stem cell transplantation | |
IL279172A (en) | Methods for generating hematopoietic stem cells | |
EP3453753A4 (en) | Method for subculturing pluripotent stem cells | |
GB201807944D0 (en) | Compositions and methods for haematopoietic stem cell transplantation | |
IL257678A (en) | Methods for stem cell transplantation | |
EP3383182A4 (en) | Methods for generating functional hematopoietic stem cells | |
EP4240346A4 (en) | Methods for allogeneic hematopoietic stem cell transplantation | |
PL3436568T3 (en) | Culture medium for pluripotent stem cells | |
HK1247639A1 (en) | Medium composition for culturing stem cells | |
EP3419617A4 (en) | Highly engraftable hematopoietic stem cells | |
IL281751A (en) | Methods for differentiating mesenchymal stem cells | |
EP3574088A4 (en) | Methods of enhancing engraftment activity of hematopoietic stem cells | |
IL277878A (en) | Compositions and methods for stem cell transplant | |
WO2015171852A3 (en) | Methods and compositions for non-cytotoxic stem cell transplantation | |
IL314599A (en) | Cell culture methods | |
IL280465A (en) | Methods for gene modification of hematopoietic cells | |
IL294152A (en) | Method for culturing hematopoietic stem cells | |
IL258267B (en) | Methods for propagating mesenchymal stem cells (msc) for use in transplantation | |
IL273987A (en) | Methods for differentiating mesenchymal stem cells | |
LT3344305T (en) | Synthetic niche matrices for stem cell culture |